The signalling cascade from initial stimulus to downstream effector — and where therapeutic intervention is possible at each node.
Cell cycle progression from G1 to S phase is governed by the cyclin D-CDK4/6 complex, which phosphorylates the retinoblastoma protein (Rb). Hyperphosphorylated Rb releases the transcription factor E2F, enabling transcription of S-phase entry genes and commitment to DNA replication and cell division. In hormone receptor-positive (HR+) breast cancer, oestrogen signalling drives cyclin D1 overexpression and CDK4/6 activation, generating constitutive Rb phosphorylation and G1 bypass — a primary mechanism of resistance to endocrine monotherapy. CDK4/6 inhibitors restore G1 arrest in HR+ tumours by preventing Rb phosphorylation, synergising with endocrine therapy to deepen and prolong cell cycle blockade.
Three CDK4/6 inhibitors are approved for HR+/HER2-negative advanced breast cancer: palbociclib (21 days on/7 days off), ribociclib (21 days on/7 days off), and abemaciclib (continuous twice daily). All three agents demonstrated significant PFS improvement in combination with aromatase inhibitors (AIs) in first-line trials (PALOMA-2, MONALEESA-2, MONARCH-3) and with fulvestrant in second-line trials. Ribociclib has demonstrated overall survival benefit in pre/perimenopausal women (MONALEESA-7) and postmenopausal women (MONALEESA-3), establishing the class as the standard of care backbone for first-line HR+/HER2- advanced breast cancer across menopausal status.
Abemaciclib's approval in the adjuvant setting (monarchE trial) for high-risk early HR+/HER2- breast cancer marked a significant expansion of CDK4/6 inhibitor indications, demonstrating durable invasive disease-free survival benefit particularly in patients with node-positive disease and either high Ki-67 or clinical high-risk features. The primary toxicity differentiating the three agents is neutropenia (more frequent with palbociclib and ribociclib) versus diarrhoea (more prominent with abemaciclib), with ribociclib carrying a QTc prolongation monitoring requirement. ESR1 mutation in circulating tumour DNA is an emerging biomarker of acquired endocrine resistance, informing subsequent therapy selection.
Upstream blockade vs downstream blockade — understanding the distinction is critical for treatment selection and sequencing.
Clinically actionable insights for treatment selection and sequencing
Cell cycle progression from G1 to S phase is governed by the cyclin D-CDK4/6 complex, which phosphorylates the retinoblastoma protein (Rb).
Hyperphosphorylated Rb releases the transcription factor E2F, enabling transcription of S-phase entry genes and commitment to DNA replication and cell division.
In hormone receptor-positive (HR+) breast cancer, oestrogen signalling drives cyclin D1 overexpression and CDK4/6 activation, generating constitutive Rb phosphorylation and G1 bypass — a primary mechanism of resistance to endocrine monotherapy.
CDK4/6 inhibitors restore G1 arrest in HR+ tumours by preventing Rb phosphorylation, synergising with endocrine therapy to deepen and prolong cell cycle blockade.
Guidelines, trials, clinical briefs, podcasts and CPD connected to this pathway.
Get Oncology Drug Science updates, related trials and education resources in your ClinicaliQ preferences.
Complete the reflective questions and self-assessment to claim your CPD certificate for this molecular mechanism hub.
Go to CPD Centre →